Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Society siteadmin2020-11-07T02:27:05-08:00October 2, 2019|
Dynacure Wins Ernst & Young’s Prix “Born Global” Award siteadmin2020-11-07T02:28:09-08:00September 18, 2019|
Dynacure to Present at Chardan’s 3rd Annual Genetic Medicines Conference siteadmin2020-11-07T02:29:21-08:00September 11, 2019|
Dynacure Appoints David Garrett as Chief Financial Officer siteadmin2020-11-07T02:30:36-08:00September 3, 2019|
Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:31:59-08:00August 8, 2019|
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:35:45-08:00April 30, 2019|
Dynacure receives Research Grant from the Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance to Expand Development of Lead Antisense Program Dyn101 for Rare Disease ‘Centro Nuclear Myopathies’ (CNM) siteadmin2020-11-07T02:37:31-08:00April 25, 2019|
Dynacure promotes Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer siteadmin2020-11-07T02:38:39-08:00February 12, 2019|
Dynacure appoints Georges Gemayel (PhD) as Chairman to its Board of Directors siteadmin2020-11-07T02:39:50-08:00October 9, 2018|
Dynacure names Chris Freitag (MD) Chief Medical Officer siteadmin2020-11-07T02:46:21-08:00July 10, 2018|
